Cargando…
What do we know and when do we know it?
Two essential aspects of virtual screening are considered: experimental design and performance metrics. In the design of any retrospective virtual screen, choices have to be made as to the purpose of the exercise. Is the goal to compare methods? Is the interest in a particular type of target or all...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270923/ https://www.ncbi.nlm.nih.gov/pubmed/18253702 http://dx.doi.org/10.1007/s10822-008-9170-2 |
_version_ | 1782151785766453248 |
---|---|
author | Nicholls, Anthony |
author_facet | Nicholls, Anthony |
author_sort | Nicholls, Anthony |
collection | PubMed |
description | Two essential aspects of virtual screening are considered: experimental design and performance metrics. In the design of any retrospective virtual screen, choices have to be made as to the purpose of the exercise. Is the goal to compare methods? Is the interest in a particular type of target or all targets? Are we simulating a ‘real-world’ setting, or teasing out distinguishing features of a method? What are the confidence limits for the results? What should be reported in a publication? In particular, what criteria should be used to decide between different performance metrics? Comparing the field of molecular modeling to other endeavors, such as medical statistics, criminology, or computer hardware evaluation indicates some clear directions. Taken together these suggest the modeling field has a long way to go to provide effective assessment of its approaches, either to itself or to a broader audience, but that there are no technical reasons why progress cannot be made. |
format | Text |
id | pubmed-2270923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-22709232008-03-21 What do we know and when do we know it? Nicholls, Anthony J Comput Aided Mol Des Article Two essential aspects of virtual screening are considered: experimental design and performance metrics. In the design of any retrospective virtual screen, choices have to be made as to the purpose of the exercise. Is the goal to compare methods? Is the interest in a particular type of target or all targets? Are we simulating a ‘real-world’ setting, or teasing out distinguishing features of a method? What are the confidence limits for the results? What should be reported in a publication? In particular, what criteria should be used to decide between different performance metrics? Comparing the field of molecular modeling to other endeavors, such as medical statistics, criminology, or computer hardware evaluation indicates some clear directions. Taken together these suggest the modeling field has a long way to go to provide effective assessment of its approaches, either to itself or to a broader audience, but that there are no technical reasons why progress cannot be made. Springer Netherlands 2008-02-06 2008-03 /pmc/articles/PMC2270923/ /pubmed/18253702 http://dx.doi.org/10.1007/s10822-008-9170-2 Text en © The Author(s) 2008 |
spellingShingle | Article Nicholls, Anthony What do we know and when do we know it? |
title | What do we know and when do we know it? |
title_full | What do we know and when do we know it? |
title_fullStr | What do we know and when do we know it? |
title_full_unstemmed | What do we know and when do we know it? |
title_short | What do we know and when do we know it? |
title_sort | what do we know and when do we know it? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270923/ https://www.ncbi.nlm.nih.gov/pubmed/18253702 http://dx.doi.org/10.1007/s10822-008-9170-2 |
work_keys_str_mv | AT nichollsanthony whatdoweknowandwhendoweknowit |